{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:40:02Z","timestamp":1784194802819,"version":"3.55.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2010,10,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated symptomatic patients with chronic lymphocytic leukemia. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients (n = 102) received fludarabine 25 mg\/m<jats:sup>2<\/jats:sup> intravenously days 1 to 5 and rituximab 50 mg\/m<jats:sup>2<\/jats:sup> day 1, 325 mg\/m<jats:sup>2<\/jats:sup> day 3, and 375 mg\/m<jats:sup>2<\/jats:sup> day 5 of cycle 1 and then 375 mg\/m<jats:sup>2<\/jats:sup> day 1 of cycles 2 to 6; fludarabine plus rituximab (FR) administration was repeated every 28 days for six cycles. Three months after completion of FR, patients with stable disease or better response received subcutaneous alemtuzumab 3 mg day 1, 10 mg day 3, and 30 mg day 5 and then 30 mg three times per week for 5 weeks. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Overall response (OR), complete response (CR), and partial response (PR) rates were 90%, 29%, and 61% after FR, respectively; 15% of patients were minimal residual disease (MRD) negative. Of 102 patients, 58 received alemtuzumab; 28 (61%) of 46 patients achieving PR after FR attained CR after alemtuzumab. By intent to treat (n = 102), OR and CR rates were 90% and 57% after alemtuzumab, respectively; 42% of patients became MRD negative. With median follow-up of 36 months, median PFS was 36 months, 2-year PFS was 72%, and 2-year OS was 86%. In patients achieving CR after FR, alemtuzumab was associated with five deaths resulting from infection (viral and Listeria meningitis and Legionella, cytomegalovirus, and Pneumocystis pneumonias), which occurred up to 7 months after last therapy. The study was amended to exclude CR patients from receiving alemtuzumab. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Alemtuzumab consolidation improved CR and MRD-negative rates after FR induction but caused serious infections in patients who had already achieved CR after induction and did not improve 2-year PFS or survival. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2010.29.7978","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T03:32:15Z","timestamp":1281411135000},"page":"4500-4506","source":"Crossref","is-referenced-by-count":65,"title":["Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101"],"prefix":"10.1200","volume":"28","author":[{"given":"Thomas S.","family":"Lin","sequence":"first","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Donohue","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret S.","family":"Lucas","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva E.","family":"Hoke","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Bengtson","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanti R.","family":"Rai","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Atkins","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"From The Ohio State University, Columbus, OH; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; Southeast Cancer Control Consortium, Goldsboro, NC; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Long Island Jewish Medical Center, New Hyde Park, NY; University of Iowa, Iowa City, IA; and University of Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.325.325","volume":"112","author":"Hallek M","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1191"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11871"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403354"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07394.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23271"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903150839"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6037"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B21","first-page":"163","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6944"},{"key":"B27","volume":"112","author":"Friedberg JW","year":"2008","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.922.922"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-020735"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2010.29.7978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:37:07Z","timestamp":1653521827000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.29.7978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,10]]},"references-count":29,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2010,10,10]]}},"alternative-id":["10.1200\/JCO.2010.29.7978"],"URL":"https:\/\/doi.org\/10.1200\/jco.2010.29.7978","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,10]]}}}